Cancer Cell Inhibitory Autophosphorylation of RAF Kinase in vitro and in cells
暂无分享,去创建一个
F. McCormick | M. Holderfield | D. Stuart | Mohammad Hekmat-Nejad | Huili Zhai | T. Nagel | Laura Tandeske | Stephen Hardy | John E. Tellew | Hanne Merritt | John Chan | M. Wallroth | Tobi E. Nagel
[1] A. Hauschild,et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. von Deimling,et al. Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.
[3] Alma L. Burlingame,et al. A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK , 2011, Nature.
[4] D. Morrison,et al. RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling , 2011, Current Biology.
[5] U. Rapp,et al. Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase* , 2011, The Journal of Biological Chemistry.
[6] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[7] Damien Kee,et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. , 2010, Cancer cell.
[8] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[9] J. Dering,et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. , 2010, Neoplasia.
[10] R. Radinsky,et al. Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth , 2010, Molecular Cancer Therapeutics.
[11] M. Belvin,et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.
[12] Chao Zhang,et al. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.
[13] J. Reis-Filho,et al. Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.
[14] Marc Therrien,et al. A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.
[15] G. Schwartz,et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[17] M. Noble,et al. How Tyrosine 15 Phosphorylation Inhibits the Activity of Cyclin-dependent Kinase 2-Cyclin A* , 2007, Journal of Biological Chemistry.
[18] T. Graeber,et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants , 2006, Proceedings of the National Academy of Sciences.
[19] K. Hemminki,et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. , 2005, The Journal of investigative dermatology.
[20] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[21] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[22] K. Guan,et al. Positive and negative regulation of Raf kinase activity and function by phosphorylation , 2001, The EMBO journal.
[23] F. McCormick,et al. Activation of c‐Raf‐1 by Ras and Src through different mechanisms: activation in vivo and in vitro , 1997, The EMBO journal.
[24] T. Traut,et al. Physiological concentrations of purines and pyrimidines , 1994, Molecular and Cellular Biochemistry.
[25] D. Morrison,et al. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase , 1993, Molecular and cellular biology.
[26] Kathleen L. Gould,et al. Tyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis , 1989, Nature.
[27] D. Beach,et al. Reversible tyrosine phosphorylation of cdc2: Dephosphorylation accompanies activation during entry into mitosis , 1989, Cell.
[28] E. Jonasch,et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. , 2009, Clinical genitourinary cancer.
[29] W. Kolch,et al. Protein kinase C alpha activates RAF-1 by direct phosphorylation. , 1993, Nature.